Bictegravir vs Elvitegravir

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV integrase · full HIV pipeline

Bictegravir · Biktarvy

Marketed by Gilead Sciences

Approved in HIVsmall molecule
Reliable signal

NCT02607956 · Phase 3 · completed

This was a randomized, double-blind, active-controlled Phase 3 trial in 657 treatment-naive HIV-1 adults, powered for non-inferiority with a 12% margin. The primary endpoint was the FDA snapshot proportion with HIV-1 RNA <50 copies/mL at Week 48, a clinical virologic endpoint. The pre-specified non-inferiority comparison was met: B/F/TAF 89.4% vs DTG+F/TAF 92.9%, difference -3.5 (95.002% CI -7.9 to 1.0), with the confidence interval entirely within the 12% margin; the superiority test was not significant.

Next expected readout: December 2026 · NCT06830668 (registry estimate)

Reported efficacy

Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Participants with HIV-1 RNA ≥50 copies/mL at week 48 (FDA snapshot): 0.4% with B/F/TAF vs 1.1% with dolutegravir plus emtricitabine/tenofovir alafenamide; difference -0.7% (95% CI -2.8% to 1.0%), inside the pre-specified 4% non-inferiority margin (CT.gov posted analysis). (met)

Result source: NCT03110380

Elvitegravir · Stribild

Marketed by Gilead Sciences and partners

Approved in HIVsmall molecule
Partial signal

NCT01095796 · Phase 3 · completed

Participants were randomized and quadruple-blinded to Stribild or active-controlled Atripla, with 348 and 352 treated participants analyzed, respectively. The primary week-48 virologic endpoint met the prespecified non-inferiority criterion, but HIV-1 RNA suppression is a surrogate endpoint rather than a hard clinical or endoscopic outcome.

Reported efficacy

The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48: The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48 (Week 48): Stribild 87.6% vs Atripla 84.1% (met)

Result source: NCT01095796

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBictegravirElvitegravir
HIV-1 RNA below 50 copies/mL (week 48)92.4% vs 93%vs ABC/DTG/3TCwk 48 · n 314NCT02607930
5 other results
  • 81.5% vs 84.1% wk 144 · n 314 · Phase 3 · secondary NCT02607930
  • 87.9% vs 89.8% wk 96 · n 314 · Phase 3 · secondary NCT02607930
  • 93.3% vs 91.1% wk 48 · n 284 · Phase 3 · secondary NCT03110380
  • 96.9% vs 93.9% wk 24 · n 65 · Phase 2 · primary NCT02397694
  • 96.9% vs 90.9% wk 48 · n 65 · Phase 2 · secondary NCT02397694
87.6% vs 84.1%vs Atriplawk 48 · n 348NCT01095796
34 other results
  • 91.6% vs 88.5% wk 48 · n 431 · Phase 3 · primary NCT01797445
  • 87.2% vs 80.8% wk 48 · n 289 · Phase 3 · primary NCT01705574
  • 93.1% vs 92.8% wk 48 · n 435 · Phase 3 · primary NCT01780506
  • 59% vs 57.8% wk 48 · n 351 · Phase 3 · primary NCT00708162
  • 93.8% vs 87.1% wk 48 · n 290 · Phase 3 · primary NCT01475838
  • 93.4% vs 88.1% wk 48 · n 290 · Phase 3 · primary NCT01495702
  • 89.5% vs 86.8% wk 48 · n 353 · Phase 3 · primary NCT01106586
  • 80.2% vs 75.3% wk 144 · n 348 · Phase 3 · secondary NCT01095796
  • 86.9% vs 83.1% wk 144 · n 435 · Phase 3 · secondary NCT01780506
  • 77.6% vs 74.6% wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 84.2% vs 81.5% wk 96 · n 348 · Phase 3 · secondary NCT01095796
  • 92.8% vs 89.1% wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 84% vs 82.3% wk 96 · n 431 · Phase 3 · secondary NCT01797445
  • 89.2% vs 88.2% wk 96 · n 435 · Phase 3 · secondary NCT01780506
  • 47.6% vs 45% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 52.4% vs 53% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 53.6% vs 56.4% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 86.9% vs 69.8% wk 96 · n 290 · Phase 3 · secondary NCT01475838
  • 86.6% vs 80.4% wk 96 · n 290 · Phase 3 · secondary NCT01495702
  • 83.3% vs 82.3% wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 85.9% vs 83.2% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 88.8% vs 85.5% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 59.8% vs 57.5% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 61% vs 60.7% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 86.1% vs 84.8% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 91.5% vs 88.5% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 76.1% vs 78.1% wk 192 · n 71 · Phase 3 · secondary NCT01095796
  • 78.4% vs 73.1% wk 192 · n 74 · Phase 3 · secondary NCT01106586
  • 88.4% vs 89.7% wk 24 · n 112 · Phase 2 · primary NCT01497899
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · primary NCT00869557
  • 88.4% vs 87.9% wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 89.6% vs 87% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 91.7% vs 82.6% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · secondary NCT00869557
HIV-1 RNA 50 copies/mL or more (week 48)0.4% vs 1.1%vs DTG + F/TAFwk 48 · n 284NCT03110380—Not reported
CD4 count, change (week 48)278 vs 289vs DTG + F/TAFwk 144 · n 262NCT02607956
6 other results
  • 299 vs 317 wk 144 · n 255 · Phase 3 · secondary NCT02607930
  • 237 vs 281 wk 96 · n 269 · Phase 3 · secondary NCT02607956
  • 287 vs 288 wk 96 · n 276 · Phase 3 · secondary NCT02607930
  • 180 vs 201 wk 48 · n 290 · Phase 3 · secondary NCT02607956
  • 235 vs 228 wk 48 · n 294 · Phase 3 · secondary NCT02607930
  • 18 vs 36 wk 48 · n 262 · Phase 3 · secondary NCT03110380
321 vs 300vs Atriplawk 144 · n 348NCT01095796
26 other results
  • 323 vs 310 wk 144 · n 379 · Phase 3 · secondary NCT01780506
  • 280 vs 293 wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 295 vs 273 wk 96 · n 348 · Phase 3 · secondary NCT01095796
  • 360 vs 328 wk 192 · n 348 · Phase 3 · secondary NCT01095796
  • 60 vs 42 wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 274 vs 260 wk 96 · n 369 · Phase 3 · secondary NCT01797445
  • 285 vs 271 wk 96 · n 395 · Phase 3 · secondary NCT01780506
  • 205 vs 198 wk 96 · n 231 · Phase 3 · secondary NCT00708162
  • 61 vs 71 wk 96 · n 255 · Phase 3 · secondary NCT01475838
  • 83 vs 101 wk 96 · n 256 · Phase 3 · secondary NCT01495702
  • 256 vs 261 wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 338 vs 340 wk 192 · n 353 · Phase 3 · secondary NCT01106586
  • 239 vs 206 wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 225 vs 200 wk 48 · n 404 · Phase 3 · secondary NCT01797445
  • 221 vs 212 wk 48 · n 263 · Phase 3 · secondary NCT01705574
  • 235 vs 221 wk 48 · n 413 · Phase 3 · secondary NCT01780506
  • 207 vs 211 wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 56 vs -1 wk 48 · n 102 · Phase 3 · secondary NCT02616783
  • 138 vs 147 wk 48 · n 267 · Phase 3 · secondary NCT00708162
  • 40 vs 32 wk 48 · n 270 · Phase 3 · secondary NCT01475838
  • 56 vs 58 wk 48 · n 270 · Phase 3 · secondary NCT01495702
  • 48 vs -4 wk 24 · n 99 · Phase 3 · secondary NCT02616783
  • 177 vs 204 wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 240 vs 166 wk 48 · n 45 · Phase 2 · secondary NCT00869557
  • 165 vs 179 wk 24 · n 112 · Phase 2 · secondary NCT01497899
  • 161 vs 117 wk 24 · n 44 · Phase 2 · secondary NCT00869557

HIV-1 RNA below 50 copies/mL (week 48)

Bictegravir
92.4% vs 93%vs ABC/DTG/3TCwk 48 · n 314NCT02607930
5 other results
  • 81.5% vs 84.1% wk 144 · n 314 · Phase 3 · secondary NCT02607930
  • 87.9% vs 89.8% wk 96 · n 314 · Phase 3 · secondary NCT02607930
  • 93.3% vs 91.1% wk 48 · n 284 · Phase 3 · secondary NCT03110380
  • 96.9% vs 93.9% wk 24 · n 65 · Phase 2 · primary NCT02397694
  • 96.9% vs 90.9% wk 48 · n 65 · Phase 2 · secondary NCT02397694
Elvitegravir
87.6% vs 84.1%vs Atriplawk 48 · n 348NCT01095796
34 other results
  • 91.6% vs 88.5% wk 48 · n 431 · Phase 3 · primary NCT01797445
  • 87.2% vs 80.8% wk 48 · n 289 · Phase 3 · primary NCT01705574
  • 93.1% vs 92.8% wk 48 · n 435 · Phase 3 · primary NCT01780506
  • 59% vs 57.8% wk 48 · n 351 · Phase 3 · primary NCT00708162
  • 93.8% vs 87.1% wk 48 · n 290 · Phase 3 · primary NCT01475838
  • 93.4% vs 88.1% wk 48 · n 290 · Phase 3 · primary NCT01495702
  • 89.5% vs 86.8% wk 48 · n 353 · Phase 3 · primary NCT01106586
  • 80.2% vs 75.3% wk 144 · n 348 · Phase 3 · secondary NCT01095796
  • 86.9% vs 83.1% wk 144 · n 435 · Phase 3 · secondary NCT01780506
  • 77.6% vs 74.6% wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 84.2% vs 81.5% wk 96 · n 348 · Phase 3 · secondary NCT01095796
  • 92.8% vs 89.1% wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 84% vs 82.3% wk 96 · n 431 · Phase 3 · secondary NCT01797445
  • 89.2% vs 88.2% wk 96 · n 435 · Phase 3 · secondary NCT01780506
  • 47.6% vs 45% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 52.4% vs 53% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 53.6% vs 56.4% wk 96 · n 351 · Phase 3 · secondary NCT00708162
  • 86.9% vs 69.8% wk 96 · n 290 · Phase 3 · secondary NCT01475838
  • 86.6% vs 80.4% wk 96 · n 290 · Phase 3 · secondary NCT01495702
  • 83.3% vs 82.3% wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 85.9% vs 83.2% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 88.8% vs 85.5% wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 59.8% vs 57.5% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 61% vs 60.7% wk 48 · n 351 · Phase 3 · secondary NCT00708162
  • 86.1% vs 84.8% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 91.5% vs 88.5% wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 76.1% vs 78.1% wk 192 · n 71 · Phase 3 · secondary NCT01095796
  • 78.4% vs 73.1% wk 192 · n 74 · Phase 3 · secondary NCT01106586
  • 88.4% vs 89.7% wk 24 · n 112 · Phase 2 · primary NCT01497899
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · primary NCT00869557
  • 88.4% vs 87.9% wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 89.6% vs 87% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 91.7% vs 82.6% wk 48 · n 48 · Phase 2 · secondary NCT00869557
  • 89.6% vs 87% wk 24 · n 48 · Phase 2 · secondary NCT00869557

HIV-1 RNA 50 copies/mL or more (week 48)

Bictegravir
0.4% vs 1.1%vs DTG + F/TAFwk 48 · n 284NCT03110380
Elvitegravir
—Not reported

CD4 count, change (week 48)

Bictegravir
278 vs 289vs DTG + F/TAFwk 144 · n 262NCT02607956
6 other results
  • 299 vs 317 wk 144 · n 255 · Phase 3 · secondary NCT02607930
  • 237 vs 281 wk 96 · n 269 · Phase 3 · secondary NCT02607956
  • 287 vs 288 wk 96 · n 276 · Phase 3 · secondary NCT02607930
  • 180 vs 201 wk 48 · n 290 · Phase 3 · secondary NCT02607956
  • 235 vs 228 wk 48 · n 294 · Phase 3 · secondary NCT02607930
  • 18 vs 36 wk 48 · n 262 · Phase 3 · secondary NCT03110380
Elvitegravir
321 vs 300vs Atriplawk 144 · n 348NCT01095796
26 other results
  • 323 vs 310 wk 144 · n 379 · Phase 3 · secondary NCT01780506
  • 280 vs 293 wk 144 · n 353 · Phase 3 · secondary NCT01106586
  • 295 vs 273 wk 96 · n 348 · Phase 3 · secondary NCT01095796
  • 360 vs 328 wk 192 · n 348 · Phase 3 · secondary NCT01095796
  • 60 vs 42 wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 274 vs 260 wk 96 · n 369 · Phase 3 · secondary NCT01797445
  • 285 vs 271 wk 96 · n 395 · Phase 3 · secondary NCT01780506
  • 205 vs 198 wk 96 · n 231 · Phase 3 · secondary NCT00708162
  • 61 vs 71 wk 96 · n 255 · Phase 3 · secondary NCT01475838
  • 83 vs 101 wk 96 · n 256 · Phase 3 · secondary NCT01495702
  • 256 vs 261 wk 96 · n 353 · Phase 3 · secondary NCT01106586
  • 338 vs 340 wk 192 · n 353 · Phase 3 · secondary NCT01106586
  • 239 vs 206 wk 48 · n 348 · Phase 3 · secondary NCT01095796
  • 225 vs 200 wk 48 · n 404 · Phase 3 · secondary NCT01797445
  • 221 vs 212 wk 48 · n 263 · Phase 3 · secondary NCT01705574
  • 235 vs 221 wk 48 · n 413 · Phase 3 · secondary NCT01780506
  • 207 vs 211 wk 48 · n 353 · Phase 3 · secondary NCT01106586
  • 56 vs -1 wk 48 · n 102 · Phase 3 · secondary NCT02616783
  • 138 vs 147 wk 48 · n 267 · Phase 3 · secondary NCT00708162
  • 40 vs 32 wk 48 · n 270 · Phase 3 · secondary NCT01475838
  • 56 vs 58 wk 48 · n 270 · Phase 3 · secondary NCT01495702
  • 48 vs -4 wk 24 · n 99 · Phase 3 · secondary NCT02616783
  • 177 vs 204 wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 240 vs 166 wk 48 · n 45 · Phase 2 · secondary NCT00869557
  • 165 vs 179 wk 24 · n 112 · Phase 2 · secondary NCT01497899
  • 161 vs 117 wk 24 · n 44 · Phase 2 · secondary NCT00869557
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety

Coverage. Bictegravir: 8 of 8 rows · Elvitegravir: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBictegravir
Rows use multiple source trials
Elvitegravir
Rows use multiple source trials
CD4
percent change · % of baseline
No placebo or comparator arm
26.1579% (n=19) @ 48wka,b,c
NCT04530630 · Phase 4 · registry result, not featured evidence
8.1% (n=49) @ 48wka,b,c
NCT01721109 · Phase 2/3 · registry result, not featured evidence
CD4+
absolute change · cells/uL
No placebo or comparator arm
382.4211 cells/uL @ 48wka,b,c
NCT04530630 · Phase 4 · registry result, not featured evidence
229 cells/uL @ 48wka,b,c
NCT01721109 · Phase 2/3 · registry result, not featured evidence
Hip BMD
percent change · % of baseline
Maintenance
-0.802% (n=278) vs -1.148% (n=281) ABC/DTG/3TC @ 48wkb,c
NCT02607930 · Phase 3 · HIV · phase 3
1.33% (n=101) vs -0.726% (n=54) Stay on Baseline Regimen @ 48wkb,c
NCT02616783 · Phase 3 · registry result, not featured evidence
HIV-1 RNA
absolute change · log
Maintenance
-3.08 vs -3.1 DTG + F/TAF log @ 96wkd,c
NCT02607956 · Phase 3 · HIV · phase 3
1 other source trial
-3.09 vs -3.1 ABC/DTG/3TC log @ 96wk
NCT02607930 · Phase 3 · HIV · phase 3
-2.26 vs -2.31 Raltegravir log @ 96wkd,c
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
Dropout rate
18.7%e
NCT02607956 · Phase 3 · HIV · phase 3
show 15 more results
17.1%B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
—B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
7.4%B/F/TAF
NCT03110380 · Phase 3
—Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · combination
5%
NCT04530630 · Phase 4 · registry result, not featured evidence
11.9%
NCT05405751 · Phase 4 · registry result, not featured evidence
—
NCT03656783 · Phase 3 · registry result, not featured evidence
4.6%BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
20%50 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
20%100 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
20%5 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
83.6%f
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 38 more results
22.2%
NCT02477527 · Phase 4 · registry result, not featured evidence
—DSG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
6.3%Delayed Switch Group (DSG)
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 0-24
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
5.1%Immediate Switch Group (ISG)
NCT02397096 · Phase 3 · registry result, not featured evidence
5.1%E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3 · registry result, not featured evidence
—Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
20%E/C/F/TAF
NCT01797445 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3 · registry result, not featured evidence
—DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
—Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
5.4%
NCT02616783 · Phase 3 · registry result, not featured evidence
—Double-Blind: E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
16%E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—Open-Label: E/C/F/TAF to E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
43.2%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
12.3%COBI+PI+2 NRTIs (Cohort 2)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
12.1%E/C/F/TDF (Cohort 1)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
10.2%
NCT01475838 · Phase 3 · registry result, not featured evidence
—All Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
8.9%Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
—Stribild (Randomized Phase)
NCT01495702 · Phase 3 · registry result, not featured evidence
80.7%
NCT01106586 · Phase 3 · registry result, not featured evidence
0%
NCT01533259 · Phase 3 · registry result, not featured evidence
14%
NCT01721109 · Phase 2/3 · registry result, not featured evidence
5.3%
NCT01497899 · Phase 2 · registry result, not featured evidence
6.3%
NCT00869557 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
1.2%e
NCT02607956 · Phase 3 · HIV · phase 3
show 15 more results
0%B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
—B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
1.1%B/F/TAF
NCT03110380 · Phase 3
—Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · combination
—
NCT04530630 · Phase 4 · registry result, not featured evidence
—
NCT05405751 · Phase 4 · registry result, not featured evidence
—
NCT03656783 · Phase 3 · registry result, not featured evidence
1.5%BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—50 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
—100 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
—25 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
—5 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
2.5%f
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 38 more results
—
NCT02477527 · Phase 4 · registry result, not featured evidence
—DSG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—DSG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
0.4%Delayed Switch Group (DSG)
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 0-24
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
—ISG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
1.6%Immediate Switch Group (ISG)
NCT02397096 · Phase 3 · registry result, not featured evidence
0.7%E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3 · registry result, not featured evidence
—Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3 · registry result, not featured evidence
—Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
0.7%E/C/F/TAF
NCT01797445 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3 · registry result, not featured evidence
—Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3 · registry result, not featured evidence
—DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
—Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
0.9%
NCT02616783 · Phase 3 · registry result, not featured evidence
—Double-Blind: E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0.9%E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—Open-Label: E/C/F/TAF to E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
2.2%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
4.1%COBI+PI+2 NRTIs (Cohort 2)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
6.1%E/C/F/TDF (Cohort 1)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
2%
NCT01475838 · Phase 3 · registry result, not featured evidence
—All Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
0.7%Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
—Stribild (Randomized Phase)
NCT01495702 · Phase 3 · registry result, not featured evidence
2.5%
NCT01106586 · Phase 3 · registry result, not featured evidence
—
NCT01533259 · Phase 3 · registry result, not featured evidence
—
NCT01721109 · Phase 2/3 · registry result, not featured evidence
0.9%
NCT01497899 · Phase 2 · registry result, not featured evidence
—
NCT00869557 · Phase 2 · registry result, not featured evidence
Serious AEs
20%e
NCT02607956 · Phase 3 · HIV · phase 3
show 15 more results
14%B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
7.5%B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · HIV · phase 3
—B/F/TAF
NCT03110380 · Phase 3
12.7%Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3
9.6%Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3
9.5%Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · combination
5%
NCT04530630 · Phase 4 · registry result, not featured evidence
4%
NCT05405751 · Phase 4 · registry result, not featured evidence
0%
NCT03656783 · Phase 3 · registry result, not featured evidence
—BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
6.2%BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
0%50 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0%100 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT02275065 · Phase 1 · registry result, not featured evidence
19.8%f
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 38 more results
0%
NCT02477527 · Phase 4 · registry result, not featured evidence
1.9%DSG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
6.4%DSG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
4.5%DSG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
2.3%DSG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
—Delayed Switch Group (DSG)
NCT02397096 · Phase 3 · registry result, not featured evidence
2.9%ISG Base Study Weeks 0-24
NCT02397096 · Phase 3 · registry result, not featured evidence
2.6%ISG Base Study Weeks 24-48
NCT02397096 · Phase 3 · registry result, not featured evidence
9.3%ISG Study Extension 1
NCT02397096 · Phase 3 · registry result, not featured evidence
4.3%ISG Study Extension 2
NCT02397096 · Phase 3 · registry result, not featured evidence
3.6%ISG Study Extension 3
NCT02397096 · Phase 3 · registry result, not featured evidence
—Immediate Switch Group (ISG)
NCT02397096 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
3%Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3 · registry result, not featured evidence
5.2%Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3 · registry result, not featured evidence
8.2%Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF
NCT01797445 · Phase 3 · registry result, not featured evidence
12.5%E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3 · registry result, not featured evidence
2.8%Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3 · registry result, not featured evidence
1.7%Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3 · registry result, not featured evidence
5.3%DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
8.7%Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
9.1%
NCT02616783 · Phase 3 · registry result, not featured evidence
16.8%Double-Blind: E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0%Open-Label: E/C/F/TAF to E/C/F/TAF
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
20.6%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
15.1%COBI+PI+2 NRTIs (Cohort 2)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
18.2%E/C/F/TDF (Cohort 1)
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
8.2%
NCT01475838 · Phase 3 · registry result, not featured evidence
8.9%All Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
—Stribild
NCT01495702 · Phase 3 · registry result, not featured evidence
8.2%Stribild (Randomized Phase)
NCT01495702 · Phase 3 · registry result, not featured evidence
16.4%
NCT01106586 · Phase 3 · registry result, not featured evidence
2.1%
NCT01533259 · Phase 3 · registry result, not featured evidence
10%
NCT01721109 · Phase 2/3 · registry result, not featured evidence
10.7%
NCT01497899 · Phase 2 · registry result, not featured evidence
4.2%
NCT00869557 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
e
diarrhoea 20.6%
headache 17.8%
nasopharyngitis 15.9%
NCT02607956 · Phase 3 · HIV · phase 3
show 12 more results
diarrhoea 17.2%
upper respiratory tract infection 14.6%
headache 14%
NCT02607930 · Phase 3 · HIV · phase 3
syphilis 8.7%
covid-19 7.9%
nasopharyngitis 7.1%
NCT02607930 · Phase 3 · HIV · phase 3
nasopharyngitis 15.5%
upper respiratory tract infection 11.6%
diarrhoea 9.2%
NCT03110380 · Phase 3
upper respiratory tract infection 7.2%
arthralgia 3.2%
bronchitis 3.2%
NCT03110380 · Phase 3
upper respiratory tract infection 8.6%
diarrhoea 6%
fatigue 6%
NCT03110380 · Phase 3 · combination
loose stool/ diarrhea 25%
NCT04530630 · Phase 4 · registry result, not featured evidence
shortness of breath 8%
NCT03656783 · Phase 3 · registry result, not featured evidence
diarrhoea 13.8%
upper respiratory tract infection 10.8%
headache 9.2%
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
50 mg
fatigue 25% (placebo 0%)
papule 25% (placebo 0%)
arthropod bite 0% (placebo 0%)
NCT02275065 · Phase 1 · registry result, not featured evidence
100 mg
arthropod bite 25% (placebo 0%)
diarrhoea 25% (placebo 0%)
headache 25% (placebo 25%)
NCT02275065 · Phase 1 · registry result, not featured evidence
25 mg
headache 25% (placebo 25%)
arthropod bite 0% (placebo 0%)
blood creatine phosphokinase increased 0% (placebo 0%)
NCT02275065 · Phase 1 · registry result, not featured evidence
5 mg
blood creatine phosphokinase increased 25% (placebo 0%)
diarrhoea 25% (placebo 0%)
headache 25% (placebo 25%)
NCT02275065 · Phase 1 · registry result, not featured evidence
f
diarrhoea 26.7%
upper respiratory tract infection 26.4%
nausea 23%
NCT01095796 · Phase 3 · monotherapy · HIV · phase 3
show 31 more results
headache 6.7%
diarrhoea 4.3%
nasopharyngitis 4.3%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 14.4%
headache 6.4%
diarrhoea 5.4%
NCT02397096 · Phase 3 · registry result, not featured evidence
covid-19 3.9%
headache 1.9%
back pain 1.3%
NCT02397096 · Phase 3 · registry result, not featured evidence
covid-19 7%
arthralgia 0%
back pain 0%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.4%
headache 6.5%
diarrhoea 4.5%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 4.4%
back pain 3.7%
diarrhoea 3%
NCT02397096 · Phase 3 · registry result, not featured evidence
nasopharyngitis 12.8%
headache 5.5%
arthralgia 5.3%
NCT02397096 · Phase 3 · registry result, not featured evidence
back pain 2.3%
arthralgia 1.7%
nasopharyngitis 1.7%
NCT02397096 · Phase 3 · registry result, not featured evidence
covid-19 8.3%
arthralgia 1.2%
diarrhoea 1.2%
NCT02397096 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 7.4%
nasopharyngitis 5.2%
diarrhoea 4.4%
NCT01815736 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 6.1%
diarrhoea 5.2%
nasopharyngitis 4.7%
NCT01815736 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.5%
diarrhoea 11.4%
nasopharyngitis 10%
NCT01815736 · Phase 3 · registry result, not featured evidence
diarrhoea 23%
headache 22.7%
upper respiratory tract infection 20.2%
NCT01797445 · Phase 3 · registry result, not featured evidence
nasopharyngitis 3.5%
headache 2.8%
arthralgia 1.4%
NCT01797445 · Phase 3 · registry result, not featured evidence
nasopharyngitis 4.2%
cough 2.5%
syphilis 2.5%
NCT01797445 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 14.6%
headache 11%
anaemia 7.3%
NCT01705574 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.3%
headache 17%
nausea 14.9%
NCT01705574 · Phase 3 · registry result, not featured evidence
nasopharyngitis 10.9%
back pain 8.2%
diarrhoea 7.3%
NCT02616783 · Phase 3 · registry result, not featured evidence
diarrhoea 25.7%
upper respiratory tract infection 21.1%
nausea 16.8%
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
cough 4.4%
syphilis 4.4%
upper respiratory tract infection 3.3%
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
diarrhoea 33.9%
upper respiratory tract infection 21.2%
headache 13.8%
NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
upper respiratory tract infection 20.5%
nasopharyngitis 19.2%
bronchitis 13.7%
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 36.4%
insomnia 21.2%
headache 18.2%
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 13.3%
upper respiratory tract infection 9.9%
diarrhoea 9.2%
NCT01475838 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 11.3%
diarrhoea 10.2%
nasopharyngitis 10.2%
NCT01495702 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 11.3%
diarrhoea 10.3%
nasopharyngitis 10.3%
NCT01495702 · Phase 3 · registry result, not featured evidence
diarrhoea 28%
upper respiratory tract infection 24.4%
nausea 22.7%
NCT01106586 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 20.8%
insomnia 12.5%
anxiety 10.4%
NCT01533259 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 36%
headache 24%
vomiting 20%
NCT01721109 · Phase 2/3 · registry result, not featured evidence
nausea 22.3%
diarrhoea 17%
fatigue 16.1%
NCT01497899 · Phase 2 · registry result, not featured evidence
diarrhoea 27.1%
fatigue 16.7%
headache 14.6%
NCT00869557 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 4 versus Phase 2/3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dPopulation context differs: baseline_threshold differs (hiv_viral_load>=500 versus hiv_viral_load>=1000); prior_therapy differs (naive versus experienced).
  5. ePopulation comparability has not been reviewed for 13 of these studies.
  6. fPopulation comparability has not been reviewed for 34 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Bictegravir

HIV RNA Less Than 50 Copies 89.4% (n=320) vs 92.9% (n=325) DTG + F/TAF @ 48wk
responder rate · % of participants
NCT02607956 · Phase 3 · HIV · phase 3
show 2 more results
84.1% (n=320) vs 86.5% (n=325) DTG + F/TAF @ 96wk
NCT02607956 · Phase 3 · HIV · phase 3
81.9% (n=320) vs 84% (n=325) DTG + F/TAF @ 144wk
NCT02607956 · Phase 3 · HIV · phase 3
HIV-1 RNA Less Than 20 82.2% (n=320) vs 87.1% (n=325) DTG + F/TAF @ 48wk
responder rate · % of participants
NCT02607956 · Phase 3 · HIV · phase 3
show 5 more results
77.5% (n=320) vs 80.3% (n=325) DTG + F/TAF @ 96wk
NCT02607956 · Phase 3 · HIV · phase 3
77.5% (n=320) vs 79.1% (n=325) DTG + F/TAF @ 144wk
NCT02607956 · Phase 3 · HIV · phase 3
87.6% (n=314) vs 87.3% (n=315) ABC/DTG/3TC @ 48wk
NCT02607930 · Phase 3 · HIV · phase 3
83.4% (n=314) vs 84.8% (n=315) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · HIV · phase 3
78% (n=314) vs 82.2% (n=315) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · HIV · phase 3
Spine BMD -0.772% (n=284) vs -0.552% (n=285) ABC/DTG/3TC @ 48wk
percent change · % of baseline
NCT02607930 · Phase 3 · HIV · phase 3
show 2 more results
-0.705% (n=256) vs -0.219% (n=258) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · HIV · phase 3
-0.371% (n=243) vs 0.035% (n=244) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · HIV · phase 3
HIV-1 RNA Ge50 Copies 0.4% (n=284) vs 1.1% (n=281) DTG + F/TAF @ 48wk
responder rate · % of participants
NCT03110380 · Phase 3
Virologic Suppression 100% (n=19) @ 48wk
event count · % of participants
No placebo or comparator arm
NCT04530630 · Phase 4 · registry result, not featured evidence · converted to % from 19 Participants as posted
Allograft Rejection 0% (n=19) @ 48wk
event count · % of participants
No placebo or comparator arm
NCT04530630 · Phase 4 · registry result, not featured evidence · converted to % from 0 Participants as posted
CD4 170 vs 173 DTG + F/TAF count @ 12wk
absolute change · count
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
190 vs 155 DTG + F/TAF count @ 24wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
258 vs 188 DTG + F/TAF count @ 48wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination

Elvitegravir

HIV-1 RNA Less Than 50 95.2% (n=21) @ 24wk
event count · % of participants
No placebo or comparator arm
NCT02477527 · Phase 4 · registry result, not featured evidence · converted to % from 20 Participants as posted
HIV-1 RNA LT 50 Copies 90.8% (n=447)
responder rate · % of participants
No placebo or comparator arm
NCT02397096 · Phase 3 · registry result, not featured evidence
show 3 more results
94.6% (n=223)
NCT02397096 · Phase 3 · registry result, not featured evidence
93.7% (n=447) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
94.6% (n=223) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
LDL-C -16.54 mg/dL @ 24wk
absolute change · mg/dL
No placebo or comparator arm
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
show 1 more result
-1.94 mg/dL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
Non-HDL-C Change mg/dL -24.74 mg/dL @ 24wk
absolute change · mg/dL
No placebo or comparator arm
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
show 1 more result
-1.31 mg/dL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
CD4+ 13.9 cells/uL
absolute change · cells/uL
No placebo or comparator arm
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
show 3 more results
18 cells/uL
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
5.1 cells/uL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
18 cells/uL @ 24wk
Change from Baseline
NCT02397096 · Phase 3 · registry result, not featured evidence
HIV-1 RNA LT 40 Copies 89.7% (n=447)
responder rate · % of participants
No placebo or comparator arm
NCT02397096 · Phase 3 · registry result, not featured evidence
show 3 more results
93.3% (n=223)
NCT02397096 · Phase 3 · registry result, not featured evidence
92.8% (n=447) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
93.3% (n=223) @ 24wk
NCT02397096 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Ge50 Copies 1.6% (n=447)
responder rate · % of participants
No placebo or comparator arm
NCT02397096 · Phase 3 · registry result, not featured evidence
show 1 more result
1.8% (n=223)
NCT02397096 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 97.2% (n=959) vs 93.1% (n=477) Baseline Treatment Regimen (SBR) @ 48wk
responder rate · % of participants
All Participants
NCT01815736 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 20 Copies 93.5% (n=959) vs 90.4% (n=477) Baseline Treatment Regimen (SBR) @ 48wk
responder rate · % of participants
All Participants
NCT01815736 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 20 Copies 90.6% (n=959) vs 85.3% (n=477) Baseline Treatment Regimen (SBR) @ 96wk
responder rate · % of participants
NCT01815736 · Phase 3 · registry result, not featured evidence
show 5 more results
82.4% (n=431) vs 80.7% (n=435) E/C/F/TDF @ 48wk
NCT01797445 · Phase 3 · registry result, not featured evidence
78.7% (n=431) vs 76.8% (n=435) E/C/F/TDF @ 96wk
NCT01797445 · Phase 3 · registry result, not featured evidence
86.4% (n=435) vs 87.3% (n=432) E/C/F/TDF @ 48wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
84.4% (n=435) vs 83.6% (n=432) E/C/F/TDF @ 96wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
84.6% (n=435) vs 80.1% (n=432) E/C/F/TDF @ 144wk
NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3
HIV-1 RNA Less Than 50 Copies 84.5% (n=278) @ 96wk
responder rate · % of participants
No placebo or comparator arm
NCT01705574 · Phase 3 · registry result, not featured evidence
show 11 more results
78.8% (n=33) @ 48wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
88.9% (n=33) @ 96wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
82.2% (n=73) @ 48wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
90.7% (n=73) @ 96wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
84.8% (n=33) @ 24wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
90.4% (n=73) @ 24wk
NCT01363011 · Phase 3 · registry result, not featured evidence · combination
100% (n=48) @ 12wk
NCT01533259 · Phase 3 · registry result, not featured evidence
100% (n=48) @ 24wk
NCT01533259 · Phase 3 · registry result, not featured evidence
100% (n=48) @ 48wk
NCT01533259 · Phase 3 · registry result, not featured evidence
88% (n=50) @ 24wk
NCT01721109 · Phase 2/3 · registry result, not featured evidence
88% (n=50) @ 48wk
NCT01721109 · Phase 2/3 · registry result, not featured evidence
CD4+ 265 vs 35 GEN cells/uL
absolute change · cells/uL
Extension (open-label)
NCT01705574 · Phase 3 · registry result, not featured evidence

+ 9 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bictegravir's landscape · Elvitegravir's landscape